Imunon (IMNN) Q2 2026 earnings summary

Executive summary

• IMNN-001 continues to show strong clinical progress, with Phase 3 OVATION 3 enrollment exceeding expectations and robust Phase 2 survival data, including a median 14.7-month OS increase and favorable safety profile.

• Achieved key validation milestones for IMNN-001 and TheraPlas platform, with growing scientific recognition and disciplined execution in clinical programs.

• Preliminary Phase 2 MRD study data indicate deeper antitumor responses, higher ctDNA clearance, and higher NED rates in the IMNN-001 arm.

• PlaCCine DNA vaccine platform completed a Phase 1 COVID-19 booster trial, showing safety, immunogenicity, and durable antibody responses.

• The company remains focused on advancing OVATION 3 and establishing IMNN-001 as a new standard of care in advanced ovarian cancer.

Financial highlights

• Net loss for Q2 2026 was $2.8 million ($0.54/share), and $7.1 million ($1.38/share) for H1 2026, up from $6.8 million in H1 2025.

• Research and development expenses for Q2 2026 were $1.5 million, up from $1.2 million year-over-year, and $3.8 million for H1 2026.

• General and administrative expenses decreased to $1.3 million in Q2 2026, down 20% from $1.6 million in the prior year.

• Cash and cash equivalents stood at $6.9 million as of June 30, 2026, with $5.0 million in restricted cash.

• Accumulated deficit reached $428 million as of June 30, 2026.

Outlook and guidance

• Enrollment in the pivotal Phase 3 OVATION 3 study is ahead of plan and expected to complete by the first half of 2029.

• Current cash position and recent $10 million financing are expected to support operations through year-end 2026, but management expresses substantial doubt about the ability to continue as a going concern without additional capital.

• Additional capital will be required to fully execute the Phase 3 trial and cover G&A needs; options are being actively explored.

• The company will host an R&D Day on September 23, 2026, to provide further updates on IMNN-001 and its platform.